

Recombinant "IMS TAG" proteins : a new method for validating bottom-up matrix-assisted laser desorption/ionisation ion mobility separation mass spectrometry imaging

COLE, Laura <http://orcid.org/0000-0002-2538-6291>, MAHMOUD, Khaled, HAYWOOD-SMALL, Sarah <http://orcid.org/0000-0002-8374-9783>, TOZER, Gillian M., SMITH, David <http://orcid.org/0000-0001-5177-8574> and CLENCH, Malcolm <http://orcid.org/0000-0002-0798-831X>

Available from Sheffield Hallam University Research Archive (SHURA) at:

https://shura.shu.ac.uk/8224/

This document is the Accepted Version [AM]

Citation:

COLE, Laura, MAHMOUD, Khaled, HAYWOOD-SMALL, Sarah, TOZER, Gillian M., SMITH, David and CLENCH, Malcolm (2013). Recombinant "IMS TAG" proteins : a new method for validating bottom-up matrix-assisted laser desorption/ionisation ion mobility separation mass spectrometry imaging. Rapid Communications in Mass Spectrometry, 27 (21), 2355-2362. [Article]

Copyright and re-use policy

See http://shura.shu.ac.uk/information.html

1	Recombinant "IMS TAG" Proteins - A New Method for Validating		
2	Bottom Up Matrix Assisted Laser Desorption - Ion Mobility		
3	Separation - Mass Spectrometry Imaging (MALDI-IMS-MSI)		
4 5	Laura M Cole ¹ , Khaled Mahmoud ^{2,} , Sarah Haywood-Small ¹ ,Gillian M Tozer ³ , David P. Smith ¹ , and Malcolm R Clench ^{*1}		
6 7	¹ Biomedical Research Centre, Sheffield Hallam University, Howard Street, Sheffield, United Kingdom S1 1WB		
8	² Leeds Institute of Molecular Medicine, University of Leeds, LS2 9JT, UK		
9 10	³ Department of Oncology, The Medical School, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX		
11			
12	* Corresponding Author Professor Malcolm R Clench, Biomedical Research Centre,		
13	Sheffield Hallam University, Howard Street, Sheffield S1 1WB m.r.clench@shu.ac.uk		
14	Keywords		
15	MALDI-MSI, mass spectrometry imaging, recombinant protein, IMS-TAG, in situ		
16	tryptic digest.		
17			
18	Abstract		
19	Rationale		
20	Matrix assisted laser desorption ionisation mass spectrometry imaging (MALDI-MSI)		

21 provides a methodology to map the distribution of peptides generated by in situ 22 tryptic digestion of biological tissue. It is challenging to correlate these peptides to

- the proteins from which they arise because of the many potentially overlapping andhence interfering peptide signals generated.
- 25 Methods

A recombinant protein has been synthesised that when cleaved with trypsin yields a range of peptide standards for use as identification and quantification markers for multiple proteins in one MALDI-IMS-MSI experiment. Mass spectrometry images of the distribution of proteins in fresh frozen and formalin fixed paraffin embedded tissue samples following in situ tryptic digestion were generated by isolating signals on the basis of their m/z value and ion mobility drift time which were correlated to matching peptides in the recombinant standard.

33 Results

Tryptic digestion of the IMS-TAG protein and MALDI-MS analysis yielded values for m/z and ion mobility drift time for the signature peptides included in it. MALDI-IMS-MSI images for the distribution of the proteins HSP 90 and Vimentin, in FFPE EMT6 mouse tumours and HSP-90 and Plectin in a fresh frozen mouse fibrosarcoma were generated by extracting ion images at the corresponding m/z and drift time from the tissue samples.

40 Conclusions

The IMS-TAG approach provides a new means to confirm the identity of peptides
generated by in situ digestion of biological tissue.

43

44 Introduction

45 Matrix assisted laser desorption ionisation - mass spectrometry imaging (MALDI-46 MSI) is an advanced analytical tool that allows molecular profiling and imaging of 47 many classes of compounds including; proteins, peptides, lipids, drugs directly from 48 tissue sections. The technique was initially reported by Spengler et al. [1] but first 49 successfully applied to the study of biological tissue by Caprioli et al. in 1997 [2]. It 50 has since been improved and adapted for use in many other studies [3-5]. In the 51 most commonly used MALDI-MSI method, multiple single mass spectra are acquired 52 across a tissue section at a spatial resolution predefined by the operator (typically 53 10-200 µm). These mass spectra together generate molecular maps or images 54 which represent the distribution and the relative abundance and/or intensity of a

specific ion signal detected within the tissue section. MALDI-MSI has been shown to
be a powerful technique for direct protein analysis within tissue sections [6].

57 MALDI-MSI has been extensively applied in the study of tumour tissue and has been 58 used for discrimination between tumour and non tumour regions with no requirement 59 for predefined targets [6-9]. A relatively recent and exciting development in the technique is the use of "on-tissue" tryptic digestion in order to achieve direct 60 identification of proteins within a tissue section [10-14]. Such molecular profiling and 61 62 imaging could be described as a bottom-up shotgun approach to protein 63 identification, and the technique has been successfully applied to the analysis of both fresh frozen and formalin fixed paraffin embedded tissues (FFPE) [10-14] 64

A number of MALDI-MSI methodologies have been reported for the confirmation of protein identity using the analysis of on-tissue digests. These include the use of ion mobility separation coupled to MS/MS [13-15], accurate mass measurement [16], the use of positive controls generated from recombinant proteins [14] and the combination of immunohistochemistry and MALDI-MSI [14]. Current workflows often combine LC-MS/MS and MALDI-MSI approaches to give complementary information [4,17].

We have previously reported the use of a single recombinant protein for validation in a MALDI-MSI experiment studying the distribution of the glucose regulator protein GRP78 in pancreatic tumour samples [14]. In this work a sample of recombinant GRP78 was digested with trypsin and spotted on the sample slide containing the tumour section to be analysed (which had been prepared by on-tissue digestion) The sample slide was then analysed by MALDI-MSI in an experiment which incorporated ion mobility separation. Images were generated from ion intensity information of ions

with a selected m/z value and ion mobility drift time. The criterion for positive identification of GRP78 was that a signal with a particular combination of m/z and drift time was observed with high ion intensity in both the spot of recombinant digest and in the tissue section, i.e. a tryptic peptide of GRP78. Peptides identified in this manor were validated by in silico digestion of the GRP78 sequence.

Our aim was to synthesise a recombinant protein that when trypsinised yielded 84 peptide standards for identification and guantification of multiple proteins in one 85 86 MALDI-IMS-MSI experiment, analogous to "QconCAT" technology for LC/MS/MS 87 [18]. To construct the recombinant protein twelve peptides that we had identified as 88 tryptic fragments of target proteins in previous on-tissue digest experiments were 89 chosen (Figure 1). The standard peptide sequences were arranged in the protein 90 sequence in such a way that the charges were evenly spaced across it with the aim 91 of preventing intra cellular aggregation during expression. One of the standard 92 peptides from endothelial growth factor receptor (EGFR) incorporated a methionine 93 residue at its N-terminus and so this peptide was placed at the start of the protein 94 thus allowing the methionine amino to be incorporated during translation in E. coli. 95 In-order to aid purification a short peptide sequence (AWLEHHHHHH) containing a six histidine tag was incorporated, tyrosine was also included to give the protein a 96 97 high extinction coefficient allowing tracking during purification and reliable 98 quantification of the final protein yield. A short "stuffer sequence" containing the 99 required restriction site was also incorporated into this peptide. The final protein had 100 an expected mass of 16,667.26 Da and a predicted extinction coefficient of 9,970 101 mol/cm (Figure 1). A synthetic DNA construct was produced by translating the 102 protein sequence back to the corresponding nucleotides taking into consideration 103 codon optimisation for the *E. coli* expression system. The synthetic DNA construct

was then sub cloned into the expression vector pET23a(+) under the control of a T7
promoter and subsequently transformed into an *E. coli* BL21 DE3 strain. The protein
expression was induced during the log phase of cell growth and subsequently
purified by affinity chromatography.

108

The utility of the recombinant protein that we are terming an "IMS-TAG" protein has been tested for two applications: the study of the distribution of proteins associated with cell death and the stress response in formalin fixed paraffin embedded mouse tumour tissue [19] and the study of proteins associated with response to vascular disrupting agents in fresh frozen tissue [20].

114

115 **Experimental**

116 (i) Samples

117 (a) Formalin Fixed Paraffin Embedded (FFPE) tissue.

Formalin Fixed Paraffin Embedded (FFPE) subcutaneous EMT6 tumours were grown in syngeneic BALB/c mice. This is an established immunogenic tumour model which can be effectively cured in some circumstances [19]. Laser treatment was employed to induce a small amount of thermal necrosis ($11 \pm 2\%$, mean \pm S.E (n=6)) which was confirmed and monitored by haematoxylin and eosin (H & E) staining.

EMT6 adenocarcinoma cells (ATCC No CRL-2755) were purchased from LGC Promochem, Teddington, UK. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% v/v fetal bovine serum, antibiotics $(1 \times 10^4$ units/mL penicillin G sodium, 10 mg/mL streptomycin sulphate in 0.85% w/v saline) and 250 µg/mL fungizone. Cells were grown at 37 °C in a 100% v/v humidified incubator with a gas phase of 5% v/v CO_2 and routinely screened for Mycoplasma. For in vivo experiments, 1×10^4 EMT6 cells were subcutaneously implanted into the right flank region of anaesthetised (1.5% v/v halothane for <5 min) 7-week old male Balb/c mice (Harlan). Mice were housed on a 12 hour light – dark illumination schedule and had free access to a standard pellet diet and water. Experiments were performed with UK Home Office approval (PPL 40/2343, PPL 40/2972).

134

Mice with EMT6 tumours reaching 300mm³ then received PBS injected intravenously 135 136 via the tail vein. After 24 h, mice were anaesthetised (1.5% v/v halothane for 30 min) 137 and the tumour region was depilated with hair removal cream prior to laser light treatment. Tumours were treated 24 h later at a light dose of 138 J/cm2 with a 138 139 fluence rate of 75mW/cm2 using a 635 nm laser attached to a microlens fibre (23 140 min). Mice were killed by cervical dislocation at 24 h or post treatment. Tumours 141 were excised and fixed (0.1 M Tris buffer, pH 7.4, 0.5 g calcium acetate, and 5.0 g 142 zinc acetate and 5.0 g zinc chloride in 1 L of deionised water) overnight before 143 transferral to 70% v/v industrial methylated spirit, prior to processing for histological 144 analysis. Samples were fixed in 10% buffered formalin for 24 hours, dehydrated in 145 70% EtOH and paraffin embedded. 5 µm sections were cut using a microtome (Leica 146 Microsystems, Bucks, UK) and mounted onto a histological glass slide. Formalin 147 fixed paraffin embedded (FFPE) tissue sections were stored at room temperature 148 until further analysis.

149 (b) Fresh Frozen Mouse Fibrosarcoma Samples

150 Mice were injected sub-cutaneously in the dorsum with a 50 μ l tumour cell 151 suspension containing 1×10⁶ cells in serum-free medium. The cells employed in this

152 study were from the mouse fibrosarcoma cell line, VEGF188. This has been 153 engineered to express only the VEGF188 isoform [21]. Tumours were allowed to 154 grow to approximately 500 mm³, before CA-4-P treatment (a single dose of 100 155 mg/kg intraperitoneal). Mice were killed and tumours excised at various times after 156 treatment.

157 (ii) Preparation of Recombinant Positive Control Sample

158 The required DNA sequence was synthesised by MWG-biotech (AG Sequencing 159 Department, Fraunhoferstr, 22 D-82152, Martinsried Germany), and sub cloned into 160 the bacterial expression vector pET23a(+) (Novagen, Merck KGaA, Darmstadt, 161 Germany). The plasmid was then transformed into the E. coli strain BL21 DE3 162 (Promega Corporation, Southampton, U K). All bacterial cultures were grown in luria 163 broth (LB) media with 100 µg/mL ampicillin for selection. 10 mL of a 100 mL 164 overnight starter culture was used to inoculate 1 L of LB media. Cultures were grown 165 at 37 °C with shaking until the OD₆₀₀ reached 0.5, protein expression was induced 166 with 1 mM isopropyl-β-D-thiogalactoside (IPTG). The culture was incubated for a 167 further 2.5 h before the bacterial cells where harvested by centrifugation at 10,000 g 168 for 20 min using a Sorvall RC G+ (Thermo Scientific, Hemel Hampstead UK).

Bacterial pellets where resuspended in binding buffer (20 mM sodium phosphate + 20 mM imidazole pH 7.4) 3mL per 1 g of cells before being lysed by sonication (10 ×20 s pulses at a 35% duty cycle) using a Vibra Cell VCX 750 (750 W). Phenylmethyl sulphonyl fluoride (PMSF) (50 μ g/mL), DNase (20 μ g/mL), RNase (20 μ g/mL) was added to the lysate which was then cleared of insoluble material by centrifugation at 8,000 g for 1 h using an Eppendorf 5804R centrifuge. The clear lysate was filtered through a 0.2 μ m syringe filter and load onto a 1 mL Histrap FF

176 column (GE) at a flow rate of 2 mL/min. Protein was eluted over 20 column volumes
177 using a 0 to 100% gradient into elution buffer (20 mM sodium phosphate + 500 mM
178 imidazole pH 7.4). Fractions containing the recombinant protein were then desalted
179 into 50 mM ammonium acetate using PD10 column (GE Healthcare, Bucks, UK Ltd).

180 (iii) Tissue preparation

181 (a) FFPE Tissue

Antigen retrieval was performed by heating in a microwave oven for ~4 min at 50% power in 0.01 M tri-sodium citrate buffer (pH = 6.3). The section was cooled to room temperature, rinsed with water and then allowed to dry. It was then washed in 70% and 90% EtOH for 1 min each before being immersed in chloroform for 15 s. It was then allowed to air dry prior to trypsin and matrix deposition.*(b) Fresh Frozen Tissue*

187 Frozen tissue sections were cut into ~10 μ m, sections using a Leica CM3050 188 cryostat (Leica Microsystems, Milton Keynes UK). The sections were then freeze 189 thaw mounted on poly-lysine glass slides by warming the underside of the slide 190 gently by application of a fingertip. Mounted slides were either used immediately or 191 stored in an airtight tube at -80 °C for subsequent use.

192 (iv) In-solution and *In situ* digestion

193 Trypsin (sequence grade modified, Promega Corporation, SO16 7NS, United 194 Kingdom) digestion was performed on a 50 μ l sample of the desalted recombinant 195 protein using 1 μ l of trypsin (1mg/mL) added for 1 h plus a further 1 μ l of trypsin 196 overnight.

197 Trypsin used in this study, for on-tissue digests, was prepared in 50 mM ammonium 198 bicarbonate buffer (pH = 8.4) containing 0.5% octyl- α/β -glucoside (OcGlc) (Sigma,

199 UK). *In situ* digestion was performed on both FFPE placental tissue and fresh frozen 200 tumours sections under humid conditions; the trypsin solution, was sprayed onto the 201 sections in a series of 5 layers, at a flow rate 2μ l/ minute, using a SunCollectTM 202 automatic sprayer (SunChrom, Friedrichsdorf, Germany). Sections were then 203 incubated overnight at 37 °C (5% CO₂).

204 (v) Matrix deposition

5 mg/mL α -cynano-4-hydroxycinnamic acid (α -CHCA) mixed with aniline .Equimolar amounts of aniline were added to the CHCA solution, i.e. one millilitre of 5 mg/ml CHCA solution contained 2.4 μ L of aniline. This matrix solution was then sprayed onto the section using the SunCollect automatic sprayer. The first and second layers were sprayed at 3 μ L/min to allow a matrix seeding process. Three subsequent layers were sprayed at 3.5 μ L/min.

211 (vi) Imaging Mass Spectrometry

212 Peptide mass fingerprints and images were acquired by MALDI/IMS/MSI using a 213 SYNAPT[™] G2 HDMS system (Waters Corporation, Manchester, UK). This 214 instrument has been described in detail by Giles et al. [22] It is fitted with a variable 215 repetition rate Nd:YAG laser which was set to 1 kHZ for these experiments. 216 Instrument calibration was performed using standards consisting of a mixture of 217 polyethylene glycol (Sigma-Aldrich, Gillingham, UK) ranging between m/z 100 to 218 3000 Da prior to MALDI-IMS-MSI analysis. Imaging data were acquired in positive 219 ion sensitivity mode at a mass resolution of 10,000 FWHM with ion mobility 220 separation enabled and over the mass range 800 Da to 3,000 Da. Image acquisition 221 was performed at 100 µm spatial resolution using variable IMS wave velocity. The

IMS wave velocity parameters applied were ramped over the full IMS cycle with astart velocity (m/s) of 800 and end velocity (m/s) of 200.

224 (vii) Data Processing

Data were processed using Waters HD Imaging software release 1.1 (Waters
Corporation, Manchester, UK). The parameters used were as follows: specificity type
(*i.e.* data type) – IMS MS, Number of most intense peaks – 1,000, resolution –
10,000, low energy intensity threshold – 50. The low intensity threshold was set to
potentially allow low abundant species to be included.

230

231 Results and Discussion

232 Figure 1 shows (a) the MALDI peptide mass fingerprint obtained from an in-solution 233 digest of the recombinant protein (b) the amino acid sequence of the recombinant 234 protein synthesised and (c) a list of "signature" peptides generated and detected 235 from the protein. As can be seen from Figure 1a the [M+H]⁺ ions from each of the 236 peptides listed in 1c were discernible. Ion intensities of peptides can be very 237 different even when peptides are present in equimolar amounts [23] This 238 phenomenon was also observed for the signature peptides, for example m/z 1168.5 239 (LGIHEDSQNR) from HSP90 alpha was 5 times more intense than the signal at m/z 240 983.4 (CEVGYTGVR) from epiregulin.

241

In order to use the recombinant protein as a positive control for the validation of
MALDI-IMS-MSI data, use was made of the Waters (Manchester, UK) HDI Imaging
software. This software allows simultaneous viewing of the mass spectrum, ion

245 mobility drift time separation and selected mass spectral image. The ion to be 246 imaged can be selected on the basis of its m/z and its drift time. Figure 2 shows an 247 example of such an application. Figure 2a shows the image of the distribution of an 248 HSP-90 "signature" peptide, m/z 1168.5 (LGIHEDSQNR) in a sample of FFPE 249 mouse EMT6 tumour tissue. The image is constructed by selecting the appropriate 250 m/z value in the plot of the ion mobility separated mass spectral data (Figure 2c). In 251 Figure 2c the ion selected is shown highlighted in red, the corresponding peak in the 252 mass spectrum (Figure 2b) (taken from a selected area) is also then highlighted in 253 red. Using this methodology to select the appropriate ion mobility drift time for the 254 peptide of interest allows increased specificity and hence confidence in ion selection 255 compared to the m/z only scenario (i.e. without MS/MS data). As can be seen the 256 m/z value of interest gives a clear signal in the region of the image containing the 257 spot of digested recombinant standard (Figure 2a bottom left hand corner) and the 258 tissue..

259

A similar approach to that described above was used to image the distribution of Vimentin in the FFPE mouse EMT6 tumour tissue (Figure 2 d-f). Figure 2d shows the image of the distribution of the Vimentin "signature" peptide m/z 1093.5 (FADLSEAANR) selected on the basis of its m/z ratio and ion mobility drift time (Figures 2e and respectively). Again the distribution of the peptide in the tissue and its presence in the region of the image containing the spot of digested recombinant standard are clearly observable.

267

268 In contrast m/z 944.5 was also selected for imaging. This is a signal we have 269 previously reported as being readily observable in *in situ* digests of tissue. The signal 270 corresponds to the [M+H]+ ion of the peptide sequence AGLQFPVGR, a tryptic 271 peptide of Histone H2A [14]. This peptide sequence was not incorporated into the 272 recombinant protein sample and hence is employed here as a negative control. 273 Figure 2g shows the distribution for this signature peptide of Histone H2A in the 274 tissue and recombinant standard spot; Figure 2h its abundance in the peptide mass 275 fingerprint and Figure 2i an expanded region of the ion mobility drift time plot for this 276 sample. As can be seen, whilst in Figure 2g the signal is clearly observable in the 277 tissue, it is not observable in that region of the image containing the spot of digested 278 recombinant standard (compare these data with Figures 2a and 2d).

279

280 In our work examining the response of tumours to vascular disrupting agents we 281 have become interested in the distribution of HSP90 and Plectin in tumour tissue 282 following administration of the vascular disrupting agent combretastatin-4-AP. 283 Therefore the recombinant protein was engineered to contain the signature peptide 284 sequences LGIHEDSQNR ($[M+H]^+$ m/z 1168.5) representing HSP90-alpha, 285 GVVDSEDLELNISR $([M+H]^+ m/z 1513.7)$ representing HPS90-beta, and 286 AQAELEAQELQR ($[M+H]^+$ m/z 1385.7) and DSQDAGGFGPEDR ($[M+H]^+$ (m/z 287 1350.5) representing Plectin. Figure 3 a-c and d-f show data from the analysis of a 288 section of a fresh frozen mouse fibrosarcoma genetically engineered to express only 289 the VEGF188 isoform (21), 72 hours after administration of combretastatin-4-AP. 290 Figures 3a-c show the distribution of m/z 1168.5 isolated by m/z and drift time as 291 previously described. The m/z and drift time were optimised using signal from 292 recombinant standard with sequence LGIHEDSQNR observed in the reference spot.

Figures 3d-f show the distribution of m/z 1350.5 similarly optimised. The distribution of the peptides in the tumour tissue and the corresponding signal in the spot of recombinant IMS-TAG standard are again clearly visible, giving good confirmation that the signals identified in the tissue are arising from the same species as that in the recombinant IMS-TAG standard.

298

299 Figure 4 shows a MALDI positive ion product mass spectrum obtained from the ion 300 at *m/z* 1168.5 (LGIHEDSQNR) present in the tryptic digest of the recombinant "IMS-301 TAG" protein. The spectrum is of high quality and searching the spectrum against 302 the SwissProt protein sequence database using the MASCOT MS/MS search engine 303 (http://www.matrixscience.com) correctly identified the peptide as a tryptic fragment 304 of mouse HSP90 alpha with a MASCOT score of 65 (p<0.05 >19). The spectrum 305 was recorded using the "transfer fragmentation" feature of the Synapt instrument i.e. 306 CID occurred after the travelling wave ion mobility device but before the ions entered 307 the time of flight mass analyser. Using this mode of fragmentation precursor and 308 product ions have the same ion mobility drift time. This is shown in the inset portion 309 of Figure 4 which shows a plot of ion intensity against ion mobility drift time as a heat 310 map. As can be seen all ions in the spectrum have the same drift time.

311

The use of transfer fragmentation on Synapt type instruments in combination with recombinant "signature" peptides opens up a number of possibilities for further experimentation. We have previously demonstrated that it is possible to carry out pseudo-MRM type experiments for the targeted detection of proteins in tissue following *in situ* digests [24]. In this work we were able to image the distribution of

eight proteins in a pancreatic tumour section via the use of product ions from 317 318 "signature peptides" and high speed MRM, monitoring 26 transitions over a 3 s cycle 319 time. This was possible since the instrument used had been modified to incorporate 320 a 20 kHz laser and utilised the Applied Biosystems "Dynamic Pixel" feature to move 321 the target plate within the boundaries of each defined pixel area to improve 322 sensitivity. Figure 5 (a-b) illustrates the feasibility of this approach; shown are 323 product ion spectra for the Actin tryptic peptide AVFPSIVGRPR obtained (a) from the 324 recombinant standard and (b) directly from tissue. For each of these spectra 325 although the spectral quality is too poor to allow unambiguous database searching, 326 the y2 and y3 product ions at m/z 272.1 and 428.2 are clearly visible. Hence these 327 mass to charge values (along with their corresponding drift times) are the targets for 328 MS^e type imaging. This will be the subject of further investigation.

329 Conclusions

330 A recombinant protein has been synthesised to contain a range of "signature" 331 peptides previously identified as arising from proteins via *in situ* tryptic digestion of 332 mammalian tissue. Tryptic digests of this new type of recombinant protein, that we 333 are terming an "IMS-TAG" protein, have been used to confirm the identity of peptides 334 in *in situ* tryptic digests of fresh frozen and FFPE tissue. This was achieved by using 335 the combination of the m/z and ion mobility drift time identified for the "signature" 336 peptide in the tryptic digest of the recombinant standard and extracting from the 337 MALDI-imaging data set images to represent the distribution of only that combination 338 of *m/z* and drift time. This minimises the risk of isobaric interferences in the MALDI-339 MSI images.

340

341 IMS-TAG proteins can be synthesised to contain any desired peptides and we are 342 currently investigating the utility of the IMS-TAG approach for MS^e pseudo MRM 343 experiments for targeted protein imaging and the incorporation of multiple 344 isotopically labelled peptides as a potential source of internal standards for protein 345 quantification in MALDI-MSI.

346

347 Acknowledgements

Laura Cole is funded by Programme Grant C1276/A10345 from Cancer Research
UK and EPSRC with additional funding from MRC and Department of Health
England.

351 References

352 1. B. Spengler, M. Hubert, R. Kaufmann, in Proc. 42nd Conf. Mass Spectrometry
353 and Allied Topics, Chicago, Illinois, 1994, p. 1041.

2. R. M. Caprioli, T. B. Farmer and J. Gile. Molecular imaging of biological samples:
localization of peptides and proteins using MALDI-TOF MS *Anal. Chem.* 1997; 69,
4751.

357 3. L. A. McDonnell, R. M. A. Heeren. Imaging mass spectrometry. Mass Spectrom.
358 Rev. 2007, 26, 606

4. S. Francese and M. R. Clench. "MALDI Mass Spectrometry Imaging, a New
Frontier in Biostructural Techniques: Applications in Biomedicine". in "Mass
Spectrometry for Microbial Proteomics" Ed Shah and Garbia, Wiley, London (2010).

- 362 5. H. Gagnon, J. Franck, M. Wisztorski, R. Day, I. Fournier, M. Salzet. Targeted
 363 Mass spectrometry Imaging: Specific Targeting Mass Spectrometry imaging
- technologies from history to perspective Prog Histochem Cytochem 2012,47, 133.
- 365 6. L. A. McDonnell, G. L. Corthals, S. M. Willems, A. Van. Remoortere, R. J. M.
- 366 Van Zeijl, A. M. Deelder. Peptide and protein imaging mass spectrometry in cancer
- 367 research. J Proteom. 2010, **73.** 1921.
- 368 7. K. Schwamborn, R. C. Krieg, M. Reska, G. Jakse, R. Knuechel, A.
- 369 Wellmann. Identifying prostate carcinoma by MALDI-Imaging. International Journal
- 370 of Molecular Medicine. 2007, **20**, 155.
- 8. S.O. Deininger, M.P. Ebert, A. Futterer, M. Gerhard, C. Rocken. MALDI imaging
 combined with hierarchical clustering as a new tool for the interpretation of complex
 human cancers J Proteome Res, 2008, 7, 5230.
- 374 9. M.C. Djidja, E. Claude, M. F. Snel, S. Francese, P. Scriven, V. Carolan, M. R.
- 375 Clench. Novel molecular tumour classification using MALDI-mass spectrometry
- imaging of tissue micro-array Anal Bioanal Chem, 2010, **397**, 587.
- 377 10. S. Shimma , M. Furuta , K. Ichimura , Y. Yoshida , M. Setou. A Novel
 378 Approach to *In situ* Proteome Analysis Using Chemical Inkjet Printing Technology
 379 and MALDI-QIT-TOF Tandem Mass Spectrometer. Journal of Mass Spectrometry
 380 Society Japan.2006, **54**, 133.
- 11. R. Lemaire, A. Desmons, J. C. Tabet, R. Day, M. Salzet, I. Fournier. I
 Direct analysis and MALDI imaging of formalin-fixed, paraffin-embedded tissue
 sections. Journal of Proteome Research 2007, 6, 1295.

M. R. Groseclose, M. Andersson, W. M. Hardesty, R. M. Caprioli.
Identification of proteins directly from tissue: *in situ* tryptic digestions coupled with
imaging mass spectrometry. Journal of Mass Spectrometry. 2007, 42, 254.

M-C. Djidja, S. Francese, P. M. Loadman, C. W. Sutton, P. Scriven, E.
Claude, M. F. Snel, J. Franck, Salzet M, Clench MR. "Detergent addition to tryptic
digests and Ion Mobility separation prior to MS/MS improves peptide yield and
Protein Identification for *in situ* Proteomic Investigation of Frozen and FFPE
Adenocarcinoma tissue sections." Proteomics 2009. **9**, 2750.

14. M-C. Djidja, E. Claude, M. F. Snel, P. Scriven, S. Francese, V. A. Carolan, M. R.
Clench. MALDI-Ion Mobility Separation-Mass Spectrometry Imaging of GlucoseRegulated Protein 78 kDa (Grp78) in Human Formalin Fixed Paraffin Embedded
Pancreatic Adenocarcinoma Tissue Sections, J Proteome Res 2009, 8, 4876..

396 15. J. Stauber, L. MacaLeese, J. Franck, E. Claude, M. F. Snel, B. K. Kaletas, I. M.
397 Wiel, M. Wisztorski, I. Fournier, R. M. Heeren. *OnTissue* Protein Identification and
398 Imaging by MALDI-Ion Mobility Mass Spectrometry, J Am Soc Mass Spectrom,
399 2010, **21**, 338.

400 16. Y. Schober, T. Schramm, B. Spengler, *et al.*. Protein identification by accurate
401 mass matrix-assisted laser desorption/ionization imaging of tryptic peptides, Rapid
402 Commun. Mass Spectrom. 2011, 25, 2475.

403

404 17. O. J. R. Gustafsson, J. S. Eddes, S. Meding, S. R. McColl, M. K. Oehler, P.
405 Hoffmann. Matrix-assisted laser desorption/ionization imaging protocol for *In situ*

406 characterization of tryptic peptide identity and distribution in formalin-fixed tissue
407 Rapid Commun Mass Spectrom, 2013, 27, 655.

408 18. R. J. Beynon, M. Doherty, J. M. Pratt, S. J. Gaskell.."Multiplexed absolute
409 quantification in proteomics using artificial QCAT proteins of concatenated signature
410 peptides" Nat Meth, 2005, 2, 587.

411 19. M. Korbelik , G. Krosl, J. Krosl , G.J. Dougherty, The role of host lymphoid
412 populations in the response of mouse EMT6 tumour to photodynamic therapy,
413 Cancer Research, 1996, **56**, 5647.

20. L. M. Cole, M-C Djidja, J. Bluff, E. Claude, V. A. Carolan, M. Paley, G. M.
Tozer and M. R. Clench, "Investigation of Protein Induction in Tumour Vascular
Targeted Strategies by MALDI-MSI" Methods 2011, 54, 442.

417 21. G. M. Tozer, S. Akerman, N. A. Cross, P. R. Barber, M. A. Björndahl, O. Greco,

418 S. Harris , S. A. Hill, D. J. Honess, C. R. Ireson, K. L. Pettyjohn, V. E. Prise, C. C.

419 Reyes-Aldasoro, C. Ruhrberg, D. T. Shima, C. Kanthou . Blood Vessel Maturation

420 and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth

421 Factor-A Isoform–Producing Tumours, Cancer Res, 2008, 68, 2301.

422 22. K. Giles, J. P. Williams, I. Campuzano . Enhancements in Travelling Wave Ion
423 Mobility Resolution. Rapid Commun Mass Spectrom 2011, 25, 559.

424 23. M-L Valero, E Giralt, D Andreu, An Investigation of Residue Specific
425 Contributions to Peptide Desorption in MALDI-TOF Mass Spectrometry. Lett. Pept.
426 Sci. 1999, 6, 109.

427 24. P.J. Trim, M-C. Djidja, S.J. Atkinson, K. Oakes, L.M. Cole, D.M.G. Anderson,
428 P.J. Hart, S. Francese, M.R. Clench, A Hybrid Quadrupole Time of Flight Mass

- 429 Spectrometer Modified to Incorporate a 20kHz Nd:YVO4 Laser for MALDI-MS
- 430 Imaging, Anal Bioanal Chem 2010, **397**, 3409.

432 Legends for Figures and Tables

Figure 1: (a) MALDI-MS peptide mass fingerprint generated from an in-solution digest of the recombinant "IMS-TAG" protein produced to assist in the interpretation of MALDI-MSI images generated from *in situ* tryptic digests. The protein was designed to contain signature peptides from 10 important proteins. (b) amino acid sequence of the "IMS-TAG" protein and (c) List of peptides generated following trypsin digest of the "IMS-TAG" protein.

Figure 2: MALDI-IMS-MSI Data generated from the Analysis of FFPE EMT6 mouse 439 440 tumour tissue (a) MALDI-IMS-MSI image for the distribution of m/z 1168.5 selected 441 such that both its m/z and ion mobility drift-time matched that of the peptide 442 LGIHEDSQNR (from HSP 90) produced by in-solution digest of the recombinant 443 IMS-TAG protein, the distribution of the peptide in both the tissue and the positive 444 control spot of the recombinant standard are clearly visible. (b) Partial MALDI mass 445 spectrum of the most abundant 1,000 peaks in imaging data set the generated by 446 the Waters HD Imaging Software (c) Display of drift time vs m/z for the 1,000 most 447 intense peaks in the imaging data set generated by the Waters HD Imaging Sofware. 448 In figures 2(b) and 2(c) the peak of interest has been highlighted. (d) MALDI-IMS-449 MSI image for the distribution of m/z 1093.5 selected such that both its m/z and ion 450 mobility drift-time matched that of the peptide FADLSEAANR (from Vimentin) 451 produced by in-solution digest of the recombinant IMS-TAG protein, the distribution 452 of the peptide in both the tissue and the positive control spot of the recombinant 453 standard are clearly visible. (e) Partial MALDI mass spectrum of the most abundant 454 1.000 peaks in imaging data set the generated by the Waters HD Imaging Software 455 (f) Display of drift time vs m/z for the 1,000 most intense peaks in the imaging data 456 set generated by the Waters HD Imaging Sofware. In figures 3(b) and 3(c) the peak

of interest has been highlighted.(g) MALDI-IMS-MSI image for the distribution of m/z 457 458 944.5 believed to be AGLQFPVGR (from Histone H2A) (b) Partial MALDI mass 459 spectrum of the most abundant 1,000 peaks in imaging data set the generated by 460 the Waters HD Imaging Software (h) Display of drift time vs m/z for the 1,000 most 461 intense peaks in the imaging data set generated by the Waters HD Imaging Sofware. 462 In figures 4(b) and 4(i) the peak of interest has been highlighted. As can be seen, 463 since this peptide was not included in the recombinant IMS-TAG standard although it 464 is clearly visible in the tissue it is not highlighted in the region of the image covering 465 the spotted recombinant standard.

466 Figure 3: MALDI-IMS-MSI Data Generated from the Analysis of a fresh frozen 467 mouse fibrosarcoma genetically engineered to express only the VEGF188 isoform 468 taken 72 hours after the administration of combretastatin-4-AP. (a) MALDI-IMS-MSI 469 image for the distribution of m/z 1168.6 selected such that both its m/z and ion 470 mobility drift-time matched that of the peptide LGIHEDSQNR (from HSP90 alpha) 471 produced by in-solution digest of the recombinant IMS-TAG protein, the distribution 472 of the peptide in both the tissue and the positive control spot of the recombinant 473 standard are clearly visible. (b) Partial MALDI mass spectrum of the most abundant 474 1,000 peaks in imaging data set the generated by the Waters HD Imaging Software 475 (c) Display of drift time vs m/z for the 1,000 most intense peaks in the imaging data 476 set generated by the Waters HD Imaging Sofware. In figures 5(b) and 5(c) the peak 477 of interest has been highlighted.

478 (d) MALDI-IMS-MSI image for the distribution of m/z 1350.5 selected such that both 479 its m/z and ion mobility drift-time matched that of the peptide DSQDAGGFGPEDR 480 (from Plectin) produced by in-solution digest of the recombinant IMS-TAG protein, 481 the distribution of the peptide in both the tissue and the positive control spot of the

recombinant standard are clearly visible. (e) Partial MALDI mass spectrum of the most abundant 1,000 peaks in imaging data set the generated by the Waters HDI Imaging Software (f) Display of drift time vs *m/z* for the 1,000 most intense peaks in the imaging data set generated by the Waters HDI Imaging Sofware. In figures 3(e) and 3(f) the peak of interest has been highlighted.

487

Figure 4: MALDI positive ion product ion spectrum obtained from the ion at *m/z* 1168.5 arising from the peptide LGIHEDSQNR and present in the tryptic digest of the recombinant "IMS-TAG" protein. These data were obtained using the "transfer fragmentation" feature of the Synapt instrument and hence the precursor ion and product ions have the same ion mobility drift-time (inset box).

493


Figure 5: MALDI Positive Ion product ion spectra obtained from the ion at m/z1198.7 arising from the Actin tryptic peptide AVFPSIVGRPR obtained (a) directly from EMT6 tumour tissue (b) from the recombinant standard. The y2 ion (m/z 272) is clearly visible in each spectrum and the inset box shows the presence of the y3 (m/z 428) ion. It is suggested that even though these spectra are of low quality the combination of product ion mass and drift time would be sufficient to allow the distribution of this protein to be imaged with confidence.

501

502

503

504 Figure 1



(b) Amino acid sequence

MHL PSP TDS NFY RVN SDE VGG EAL GRA VFP SIV GRP RRL TSL VRE TFI TGL DAP RGV VDS EDL ELN ISR LGI HED SQN RFA DLS EAA NRA QAE LEL QEL QRD SQD AAG FGP EDR CEV GYT GVR VTH AVV TVP AYF NDA QRA WLE HHH HHH

(c) Peptide List

Peptide	m/z	Peptide Sequence
GRP-78	1887.9	VTHAVVTVPAYFNDAQR
EGFR	1564.7	MHLPSPTDSNFYR
HSP- 90 beta	1513.7	GVVDSEDLELNISR
Plectin	1385.7	AQAELEAQELQR
	1350.5	DSQDAGGFGPEDR
Haemoglobin beta chain	1302.6	VNSDEVGGEALGR
Tenascin	1219.6	ETFITGLD
Actin	1198.7	AVFPSIVGRPR
HSP-90 alpha	1168.5	LGIHEDSQNR
Vimentin	1093.5	FADLSEAANR
Epiregulin	983.4	CEVGYTGVR
Rho GTPase activating protein 2	844.5	RLTSLVR
Tag reporter		A WLE HHH HHH

505

506

507

508







Figure 3 513




HSP90 beta





Plectin (e)


Intensity (Counts)



514

- 515
- 516
- 517
- 518
- 519
- 520

(f)



521 Figure 4

